Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

June 2016

Feature

From the Field
06/20/2016
Stacie Hudgens, MA
Andrew Briggs, DPhil, MSc
Anna Forsythe, PharmaD, MBA, MSc
Gabriel Tremblay, DBA, MSc
Andrew J Lloyd, DPhil
Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...
Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...
...
06/20/2016
Journal of Clinical Pathways
Research Reports
06/20/2016
Nancy Ehmke, RN, MN, AOCN
Breck Hunnicutt, RN, BSN, CCRC
Hilary Biddle RN, BSN, CCRC
Christina Zelt, RN, MSN
Brooke Hoverman
Stephanie Trenkner, BS
Carlena Magley, BS
Abstract: As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their...
Abstract: As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their...
...
06/20/2016
Journal of Clinical Pathways

Column

Pharma Insights
06/20/2016
Rick Lifsitz, MBA
Larry Blandford, PharmD—Column Editor
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The...
06/20/2016
Journal of Clinical Pathways
Clinical Pathways GPS
06/20/2016
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD–Column Editor
Taha Khan, PharmD, RPh
Aspects of a medication beyond the chemical composition can have an impact on patient outcomes. Consideration of these aspects when developing clinical pathways may result in particular formulations or delivery...
Aspects of a medication beyond the chemical composition can have an impact on patient outcomes. Consideration of these aspects when developing clinical pathways may result in particular formulations or delivery...
...
06/20/2016
Journal of Clinical Pathways

Insights

Interview
06/20/2016
In the mid-1980s, cancer researchers shifted their focus from determining the location of a cancer to identifying the genetic mutations that create it.1 This shift gave birth to a new field of study known as...
In the mid-1980s, cancer researchers shifted their focus from determining the location of a cancer to identifying the genetic mutations that create it.1 This shift gave birth to a new field of study known as...
In the...
06/20/2016
Journal of Clinical Pathways
Interview
06/20/2016
  According to a recent report, prescription drug costs rose by more than 12% in 2014 and are expected to continue to rise by more than 7% through 2018.1 In addition, a study of the out-of-pocket costs...
  According to a recent report, prescription drug costs rose by more than 12% in 2014 and are expected to continue to rise by more than 7% through 2018.1 In addition, a study of the out-of-pocket costs...
...
06/20/2016
Journal of Clinical Pathways

News

Conference Coverage
06/20/2016
JCP Editors
Michael Barry, MD, PhD, clinical director at the National Centre for Pharmaceoeconomics in Dublin, Ireland, initiated the session, “Payers’ use of Independent Reports in Decision Making—Will There Be an ICER Effect,”...
Michael Barry, MD, PhD, clinical director at the National Centre for Pharmaceoeconomics in Dublin, Ireland, initiated the session, “Payers’ use of Independent Reports in Decision Making—Will There Be an ICER Effect,”...
...
06/20/2016
Journal of Clinical Pathways
Conference Coverage
06/20/2016
JCP Editors
Founded in 1995, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is one of the leading organizations promoting the research of health economics and value-based care. Currently, ISPOR is...
Founded in 1995, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is one of the leading organizations promoting the research of health economics and value-based care. Currently, ISPOR is...
...
06/20/2016
Journal of Clinical Pathways

Department

Research in Review
06/20/2016
JCP Editors
A Bundled Payments for Care Improvement model developed at New York University Langone Medical Center (NYULMC), New York City, NY, was successful at improving institutional efficiency and providing more value...
A Bundled Payments for Care Improvement model developed at New York University Langone Medical Center (NYULMC), New York City, NY, was successful at improving institutional efficiency and providing more value...
...
06/20/2016
Journal of Clinical Pathways
Research in Review
06/20/2016
JCP Editors
A review of the last decade of care for rectal cancer has found evidence of significant progress in improving patient outcomes despite a number of challenges. For their review, researchers led by Nader N...
A review of the last decade of care for rectal cancer has found evidence of significant progress in improving patient outcomes despite a number of challenges. For their review, researchers led by Nader N...
...
06/20/2016
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement